Please assess the completion status of the following clinical trial:

Trial Title: Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be ≥18 and ≤90 years of age~* Female patients can participate if they are surgically sterile or completed menopause or females capable of having children and agree not to attempt pregnancy while receiving IV study therapy and for a period of 7 days after~* Patient has a ceftazidime-resistant Gram negative pathogen that was isolated from an appropriate culture within 5 days prior to study entry (ie, within 5 days prior to Screening; the study-qualifying culture), which was determined to be the causative agent of the entry infection~Exclusion Criteria:~* Patient has an APACHE II score \>30 (cIAI patients only)~* Patient has an infection due to Gram negative pathogen that is unlikely to respond to CAZ-AVI treatment (eg, Acinetobacter spp., Stenotrophomonas spp.)~* Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant Patient is immunocompromised~* Patient has a rapidly progressive or terminal illness with a high risk of mortality due to any cause, including acute hepatic failure, respiratory failure or severe septic shock such that they are unlikely to survive the 4- to 5-week study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ceftazidime - Avibactam ( CAZ-AVI) (Type: EXPERIMENTAL): IV treatment
- Best Available Therapy (Type: ACTIVE_COMPARATOR): IV treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).